More importantly, FK866 and quercetin consistently corrected NAD+ metabolic disorders, including expressions of NMNAT1, NAPRT, and NAMPT as well as NAD+ and NAD+/NADH levels both in vitro and in vivo. The gene discussed is NAPRT; the disease is metabolic disease.